Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S

Published: Thursday, May 09, 2013
Last Updated: Thursday, May 09, 2013
Bookmark and Share
TriLink BioTechnologies Inc. announced that it has signed a licensing agreement with QuantiBact A/S to offer twisted intercalating nucleic acid (TINA) modified oligos.

TINA molecules are intercalators placed at the 5' end of primers to stabilize duplex formation. Their unique properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA may find applications wherever an enhanced Tm is required such as triplex formation or potentially even gene silencing.

"At QuantiBact we strive to make our technologies available throughout the research and diagnostic communities. We appreciate being able to work with dedicated companies that hold high recognition in the market place. The market position as well as in depth knowledge of nucleic acids embedded within TriLink will enable us to further reach our goal," says Palle Schelde, CEO, Managing Director, QuantiBact.

"At TriLink we pride ourselves on our quality and our ability to handle unique nucleic acid modifications. This makes us an ideal manufacturer of TINA oligos," stated Richard Hogrefe, Ph.D., President and CEO of TriLink. "We are excited to work with the great folks at Quantibact and see how this technology might advance molecular diagnostics."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TriLink Secures Contract for the Synthesis of Ebola Vaccine
The project aims to create a trivalent vaccine effective against aerosolized exposure to Ebola.
Friday, December 12, 2014
TriLink to Open New Early Phase Therapeutic Manufacturing Facility
Company's new 2,000 square foot diagnostic and pharmaceutical GMP production facility will be fully operational July 2014.
Tuesday, May 27, 2014
TriLink Announces New License Agreement with Biofortuna
Agreement for use of CleanAmp™ dNTPs in Biofortuna’s freeze-drying contract development and production service.
Friday, November 08, 2013
TriLink BioTechnologies Announces Agreement with American Cleanroom Systems to build cGMP Facility
Agreement signed to build a 2,000 square foot pharmaceutical cGMP production suite within San Diego facility.
Thursday, October 24, 2013
Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies
Dr. Gerald Zon, noted scientist in the field of nucleic acid research recently launched a new blog in conjunction with TriLink Biotechnologies.
Tuesday, May 21, 2013
TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S
TriLink BioTechnologies, Inc. announced that it has signed a licensing agreement with QuantiBact A/S to offer twisted intercalating nucleic acid (TINA) modified oligos.
Thursday, May 16, 2013
TriLink Enters into Distribution Agreement with Astral Scientific
The agreement allows Astral to sell Trilink's modified nucleic acid products, including over 150 modified nucleotides, custom oligonucleotides and CleanAmp™ Hot Start PCR Products. The Australian based company supplies clinical diagnostic, life science and industrial markets.
Tuesday, November 15, 2011
TriLink Announces License Agreement with Lucigen Corporation
Two companies have signed a licensing agreement for the use of TriLink’s CleanAmp™ dNTPs in Lucigen’s new Taq98™ Hot Start 2X MasterMix.
Wednesday, August 03, 2011
TriLink BioTechnologies, Inc. Awarded European Patent
TriLink BioTechnologies, Inc. announces the award of their CleanAmp™ Primer patent by the European Patent Office (EPO Patent no. 2032714).
Tuesday, May 31, 2011
TriLink Enters into Distribution Agreement with TATAA Biocenter
TriLink BioTechnologies, Inc. has entered into a distribution agreement with TATAA Biocenter (TATAA) to sell its CleanAmp™ Products.
Monday, March 28, 2011
TriLink BioTechnologies Awards Webster University CleanAmp™ ResearchReward
Dr. Mary Lai Preuss of Webster University has been given the award for map-based cloning of Arabidopsis root hair developmental mutants.
Friday, September 24, 2010
TriLink BioTechnologies, Inc. Announces License Agreement with Biofortuna Ltd
TriLink BioTechnologies, announced that it has signed a licensing agreement with Biofortuna Ltd. for use of CleanAmp™ dNTPs in Biofortuna’s freeze dried in vitro diagnostic PCR kits.
Tuesday, September 14, 2010
TriLink Enters Into Distribution and Supply Agreement with Affymetrix
Under the terms of agreement, Affymetrix will use TriLink's high quality oligonucleotides in several of their kits.
Wednesday, July 21, 2010
TriLink Awarded SBIR Phase II Grant: Chemical Determinants of DNA Ligase Fidelity
The National Institutes of Health recently awarded TriLink BioTechnologies, Inc. (TriLink) a Phase II SBIR Grant of approximately $725,000 to continue their work on developing reagents to enhance the specificity of DNA ligase.
Tuesday, June 22, 2010
TriLink BioTechnologies, Inc. Announces Supply Agreement with ETS Laboratories
TriLink BioTechnologies, Inc. (TriLink) announced that it has signed an agreement with ETS Laboratories (ETS) to supply CleanAmp™ dNTPs for use in their Scorpions™ Wine Spoilage Detection System.
Tuesday, April 27, 2010
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!